Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • ID: 3832331
  • Report
  • 85 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Affibody AB
  • Apexigen, Inc.
  • Cell Medica Limited
  • Handok Inc.
  • Novartis AG
  • MORE
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Summary

‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
- The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Affibody AB
  • Apexigen, Inc.
  • Cell Medica Limited
  • Handok Inc.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview

Therapeutics Development

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development

AbbVie Inc

Affibody AB

Anacor Pharmaceuticals, Inc.

Apexigen, Inc.

Cell Medica Limited

Handok Inc.

Immune Response BioPharma, Inc.

Novartis AG

Omnitura Therapeutics Inc.

Opsona Therapeutics Limited

Peptinov SAS

R-Pharm

Regeneron Pharmaceuticals Inc

TWi Pharmaceuticals, Inc.

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles

ABT-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-4161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-2351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMN-54 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPV-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilonacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule Inflammasome Modulator Programme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases

Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment

Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab

Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir

Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet

Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients

Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting

Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes

Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia

Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan

Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China

Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan

Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States

Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States

Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 85List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by AbbVie Inc, H2 2016

Pipeline by Affibody AB, H2 2016

Pipeline by Anacor Pharmaceuticals, Inc., H2 2016

Pipeline by Apexigen, Inc., H2 2016

Pipeline by Cell Medica Limited, H2 2016

Pipeline by Handok Inc., H2 2016

Pipeline by Immune Response BioPharma, Inc., H2 2016

Pipeline by Novartis AG, H2 2016

Pipeline by Omnitura Therapeutics Inc., H2 2016

Pipeline by Opsona Therapeutics Limited, H2 2016

Pipeline by Peptinov SAS, H2 2016

Pipeline by R-Pharm, H2 2016

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Pipeline by TWi Pharmaceuticals, Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Dormant Projects (Contd..3), H2 2016

Dormant Projects (Contd..4), H2 2016

Discontinued Products, H2 2016

Discontinued Products (Contd..1), H2 2016

Discontinued Products (Contd..2), H2 2016 74List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Affibody AB
  • Apexigen, Inc.
  • Cell Medica Limited
  • Handok Inc.
  • Novartis AG
  • MORE
According to our recently published report 'Interleukin 1 Beta – Pipeline Review, H2 2016'; Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Interleukin 1 beta is a cytokine protein encoded by the IL1B gene. It induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. It promotes Th17 differentiation of T-cells.

The report 'Interleukin 1 Beta – Pipeline Review, H2 2016' outlays comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 2, 3 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Affibody AB
Anacor Pharmaceuticals, Inc.
Apexigen, Inc.
Cell Medica Limited
Handok Inc.
Immune Response BioPharma, Inc.
Novartis AG
Omnitura Therapeutics Inc.
Opsona Therapeutics Limited
Peptinov SAS
R-Pharm
Regeneron Pharmaceuticals Inc
TWi Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll